Pieris Pharmaceuticals (PIRS) Competitors $17.30 +0.05 (+0.29%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends PIRS vs. FGEN, BYSI, KZIA, CUE, ALRN, PLX, CHRS, IOBT, CMRX, and PMVPShould you be buying Pieris Pharmaceuticals stock or one of its competitors? The main competitors of Pieris Pharmaceuticals include FibroGen (FGEN), BeyondSpring (BYSI), Kazia Therapeutics (KZIA), Cue Biopharma (CUE), Aileron Therapeutics (ALRN), Protalix BioTherapeutics (PLX), Coherus BioSciences (CHRS), IO Biotech (IOBT), Chimerix (CMRX), and PMV Pharmaceuticals (PMVP). These companies are all part of the "medical" sector. Pieris Pharmaceuticals vs. FibroGen BeyondSpring Kazia Therapeutics Cue Biopharma Aileron Therapeutics Protalix BioTherapeutics Coherus BioSciences IO Biotech Chimerix PMV Pharmaceuticals Pieris Pharmaceuticals (NASDAQ:PIRS) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, community ranking, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends. Does the MarketBeat Community favor PIRS or FGEN? FibroGen received 65 more outperform votes than Pieris Pharmaceuticals when rated by MarketBeat users. Likewise, 61.03% of users gave FibroGen an outperform vote while only 60.70% of users gave Pieris Pharmaceuticals an outperform vote. CompanyUnderperformOutperformPieris PharmaceuticalsOutperform Votes27860.70% Underperform Votes18039.30% FibroGenOutperform Votes34361.03% Underperform Votes21938.97% Do analysts rate PIRS or FGEN? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pieris Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AFibroGen 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher earnings and valuation, PIRS or FGEN? Pieris Pharmaceuticals has higher earnings, but lower revenue than FibroGen. Pieris Pharmaceuticals is trading at a lower price-to-earnings ratio than FibroGen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPieris Pharmaceuticals$20.87M1.09-$24.54M-$18.71-0.92FibroGen$147.75M0.22-$284.23M-$1.71-0.19 Is PIRS or FGEN more profitable? Pieris Pharmaceuticals has a net margin of -39.71% compared to FibroGen's net margin of -96.84%. FibroGen's return on equity of 0.00% beat Pieris Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Pieris Pharmaceuticals-39.71% -101.29% -65.00% FibroGen -96.84%N/A -40.37% Which has more risk & volatility, PIRS or FGEN? Pieris Pharmaceuticals has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, FibroGen has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Do insiders and institutionals have more ownership in PIRS or FGEN? 40.1% of Pieris Pharmaceuticals shares are held by institutional investors. Comparatively, 72.7% of FibroGen shares are held by institutional investors. 8.9% of Pieris Pharmaceuticals shares are held by insiders. Comparatively, 2.0% of FibroGen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media favor PIRS or FGEN? In the previous week, Pieris Pharmaceuticals and Pieris Pharmaceuticals both had 1 articles in the media. FibroGen's average media sentiment score of 0.00 beat Pieris Pharmaceuticals' score of -0.18 indicating that FibroGen is being referred to more favorably in the news media. Company Overall Sentiment Pieris Pharmaceuticals Neutral FibroGen Neutral SummaryFibroGen beats Pieris Pharmaceuticals on 10 of the 14 factors compared between the two stocks. Ad Chaikin AnalyticsSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). Get Pieris Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PIRS vs. The Competition Export to ExcelMetricPieris PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.84M$7.02B$5.39B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-0.929.47113.8115.12Price / Sales1.09381.571,483.2593.03Price / CashN/A47.3339.6434.05Price / Book0.805.324.665.02Net Income-$24.54M$153.56M$119.06M$225.46M7 Day Performance2.14%0.12%0.79%0.37%1 Month Performance4.53%15.23%5.65%3.57%1 Year Performance-16.83%41.16%36.76%29.42% Pieris Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PIRSPieris Pharmaceuticals2.3762 of 5 stars$17.30+0.3%N/A-14.4%$22.84M$20.87M-0.92140FGENFibroGen2.3054 of 5 stars$0.30+1.0%N/A-41.7%$30.03M$173.82M-0.18486Upcoming EarningsAnalyst ForecastShort Interest ↓BYSIBeyondSpringN/A$2.28+3.6%N/A+120.4%$88.99M$1.88M0.0080Positive NewsKZIAKazia Therapeutics1.6853 of 5 stars$5.41+16.1%$20.00+269.7%+35.7%$88.41M$20,000.000.0012Gap DownCUECue Biopharma4.6549 of 5 stars$1.81+1.7%$5.00+176.2%-24.8%$88.04M$8.30M-1.8760Positive NewsGap UpALRNAileron Therapeutics3.8501 of 5 stars$4.05+0.7%$19.00+369.1%+200.9%$87.54MN/A-1.259Upcoming EarningsShort Interest ↓News CoveragePLXProtalix BioTherapeutics1.9151 of 5 stars$1.17+3.5%$10.00+754.7%-23.1%$86.04M$65.49M-5.85200Gap UpCHRSCoherus BioSciences3.8143 of 5 stars$0.75+3.9%$7.13+850.1%-77.4%$86.03M$308.13M-1.87246Upcoming EarningsIOBTIO Biotech3.3411 of 5 stars$1.30-2.3%$9.33+617.9%+36.8%$85.65MN/A-0.9030Short Interest ↓Positive NewsGap UpCMRXChimerix4.1022 of 5 stars$0.95+1.1%$8.50+794.7%+3.1%$85.15M$144,000.00-1.0072Upcoming EarningsNews CoveragePMVPPMV Pharmaceuticals2.7396 of 5 stars$1.65-0.6%$5.75+248.5%-17.7%$85.01MN/A-1.7050 Related Companies and Tools Related Companies FibroGen Alternatives BeyondSpring Alternatives Kazia Therapeutics Alternatives Cue Biopharma Alternatives Aileron Therapeutics Alternatives Protalix BioTherapeutics Alternatives Coherus BioSciences Alternatives IO Biotech Alternatives Chimerix Alternatives PMV Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PIRS) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pieris Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pieris Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
